{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:34:57Z","timestamp":1791473697448,"version":"4.3.4"},"reference-count":51,"publisher":"Royal College of Psychiatrists","issue":"2","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["BJPsych open"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec id=\"S2056472423000157_sec_a1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Poor oral health is increasingly recognised as an important comorbidity in people with psychiatric illness. One risk factor is psychotropic-induced dry mouth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S2056472423000157_sec_a2\">\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To perform a systematic review of the severity of dry mouth due to psychotropic drugs in adults (CRD42021239725). Study quality was assessed using the Cochrane risk of bias tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S2056472423000157_sec_a3\" sec-type=\"methods\">\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We searched the following databases: PubMed, EMBASE, PsycINFO, Cochrane Central Register of Controlled Trials, CINAHL and Web of Science. We included randomised controlled trials (RCTs) measuring the severity of drug-induced hyposalivation and xerostomia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S2056472423000157_sec_a4\" sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen RCTs with 605 participants were included. Severity of drug-induced dry mouth was compared among eight drug classes and\/or against placebo. All studies were published 20 to 40 years ago and included tricyclic antidepressants (TCAs), serotonin specific reuptake inhibitors (SSRIs) and other drug classes. Meta-analysis was not feasible owing to design heterogeneity. TCAs caused more severe dry mouth, both objectively and subjectively, than placebo or other drug classes. SSRIs were generally associated with less severe symptoms. However, there was no information on antipsychotics or more recently available antidepressants, and there was minimal information on mood stabilisers. Most studies were on healthy subjects, limiting the generalisability of findings. Only one study measured both objective and subjective dry mouth, which have different clinical implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S2056472423000157_sec_a5\" sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Psychotropic-induced dry mouth is a poorly researched area, and well-designed RCTs of newer psychotropic drugs using standardised objective and subjective measures are indicated. Given the ongoing use of TCAs for treatment-resistant depression, prescribers need to remain vigilant for xerostomia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1192\/bjo.2023.15","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T05:15:42Z","timestamp":1679289342000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":23,"title":["Dry mouth effects from drugs used for depression, anxiety, schizophrenia and bipolar mood disorder in adults: systematic review"],"prefix":"10.1192","volume":"9","author":[{"given":"Cherilyn Xue Wei","family":"Teoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie","family":"Thng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serene","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Wong","family":"Taing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Y.","family":"Chaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-9216","authenticated-orcid":false,"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4021-2924","authenticated-orcid":false,"given":"Steve","family":"Kisely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"key":"S2056472423000157_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2017.12.012"},{"key":"S2056472423000157_ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12449"},{"key":"S2056472423000157_ref29","doi-asserted-by":"publisher","DOI":"10.1007\/BF00314863"},{"key":"S2056472423000157_ref35","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061427"},{"key":"S2056472423000157_ref36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s002130000664","article-title":"The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system \u2013 a randomised placebo-controlled study on healthy volunteers","volume":"154","author":"Penttil\u00e4","year":"2001","journal-title":"Psychopharmacology"},{"key":"S2056472423000157_ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-0009.2005.00347.x"},{"key":"S2056472423000157_ref43","doi-asserted-by":"publisher","DOI":"10.1177\/1721727X0600400102"},{"key":"S2056472423000157_ref24","doi-asserted-by":"publisher","DOI":"10.1007\/BF00432740"},{"key":"S2056472423000157_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32335-3"},{"key":"S2056472423000157_ref30","doi-asserted-by":"publisher","DOI":"10.1007\/BF00544244"},{"key":"S2056472423000157_ref41","doi-asserted-by":"publisher","DOI":"10.1007\/BF00427291"},{"key":"S2056472423000157_ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-014-0631-y"},{"key":"S2056472423000157_ref12","doi-asserted-by":"publisher","DOI":"10.1177\/0706743716632523"},{"key":"S2056472423000157_ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15151"},{"key":"S2056472423000157_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.04.040"},{"key":"S2056472423000157_ref21","unstructured":"21 Royal Pharmaceutical Society. Martindale: The Complete Drug Reference. Royal Pharmaceutical Society (https:\/\/www-medicinescomplete-com.ezproxy.library.uq.edu.au\/#\/browse\/martindale [cited 3 Sep 2021])."},{"key":"S2056472423000157_ref28","doi-asserted-by":"publisher","DOI":"10.1007\/BF00427684"},{"key":"S2056472423000157_ref5","doi-asserted-by":"publisher","DOI":"10.1034\/j.1601-0825.2003.03967.x"},{"key":"S2056472423000157_ref32","doi-asserted-by":"publisher","DOI":"10.1185\/03007998209109779"},{"key":"S2056472423000157_ref39","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430030608"},{"key":"S2056472423000157_ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-016-0153-9"},{"key":"S2056472423000157_ref23","unstructured":"23 National Health and Medical Research Council. Assessing Risk of Bias. National Health and Medical Research Council, 2019 (https:\/\/nhmrc.gov.au\/guidelinesforguidelines\/develop\/assessing-risk-bias [cited 3 Sep 2020])."},{"key":"S2056472423000157_ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-016-0684-7"},{"key":"S2056472423000157_ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1499-3"},{"key":"S2056472423000157_ref13","unstructured":"13 Australian Institute of Health and Welfare. Summary of Mental Health Services in Australia (updated 20 Jul 2021). Australian Institute of Health and Welfare, 2021 (https:\/\/www.aihw.gov.au\/reports\/mental-health-services\/mental-health-services-in-australia\/report-contents\/summary-of-mental-health-services-in-australia [cited 3 Sep 2021])."},{"key":"S2056472423000157_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tripleo.2007.11.008"},{"key":"S2056472423000157_ref27","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315281"},{"key":"S2056472423000157_ref31","doi-asserted-by":"publisher","DOI":"10.1177\/026988118700100305"},{"key":"S2056472423000157_ref33","first-page":"249","article-title":"Assessment of the relationship between plasma nortriptyline concentration and inhibition of salivation \u2013 single-dose study","volume":"6","author":"Jang","year":"1991","journal-title":"Asia Pac J Pharmacol"},{"key":"S2056472423000157_ref38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1981.tb00741.x"},{"key":"S2056472423000157_ref25","doi-asserted-by":"publisher","DOI":"10.1007\/BF00422502"},{"key":"S2056472423000157_ref46","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0528.2000.280303.x"},{"key":"S2056472423000157_ref47","doi-asserted-by":"publisher","DOI":"10.3109\/00016488309130932"},{"key":"S2056472423000157_ref37","first-page":"145","article-title":"Anticholinergic activity of the tricyclic antidepressants despiramine and doxepin in nondepressed volunteers","volume":"2","author":"Peterson","year":"1978","journal-title":"Commun Psychopharmacol"},{"key":"S2056472423000157_ref49","first-page":"84","article-title":"Oral and dental effects of antidepressants","volume":"39","author":"Daly","year":"2016","journal-title":"Aust Prescr"},{"key":"S2056472423000157_ref18","unstructured":"18 World Health Organization. Mental Disorders. WHO, 2019 (https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/mental-disorders [cited 3 Sep 2021])."},{"key":"S2056472423000157_ref20","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12564"},{"key":"S2056472423000157_ref40","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.137.5.433"},{"key":"S2056472423000157_ref50","doi-asserted-by":"publisher","DOI":"10.1111\/adj.12750"},{"key":"S2056472423000157_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.07.037"},{"key":"S2056472423000157_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-9969(01)00003-6"},{"key":"S2056472423000157_ref48","unstructured":"48 Rohatgi, A . WebPlotDigitizer, version 4.6. Ankit Rohatgi, 2022 (https:\/\/automeris.io\/WebPlotDigitizer [cited 6 Sep 2022])."},{"key":"S2056472423000157_ref10","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2002.0362"},{"key":"S2056472423000157_ref51","first-page":"17","article-title":"Prevalence and management of treatment-resistant depression","volume":"68","author":"Nemeroff","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"S2056472423000157_ref45","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-200410000-00023"},{"key":"S2056472423000157_ref1","doi-asserted-by":"publisher","DOI":"10.14219\/jada.2014.44"},{"key":"S2056472423000157_ref26","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.155.4.479"},{"key":"S2056472423000157_ref42","doi-asserted-by":"publisher","DOI":"10.1177\/00220345820610100901"},{"key":"S2056472423000157_ref44","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2008.0353"},{"key":"S2056472423000157_ref22","doi-asserted-by":"publisher","DOI":"10.4103\/0975-7406.137255"},{"key":"S2056472423000157_ref34","doi-asserted-by":"publisher","DOI":"10.1007\/BF00606656"}],"container-title":["BJPsych Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2056472423000157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T05:15:57Z","timestamp":1679289357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2056472423000157\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["S2056472423000157"],"URL":"https:\/\/doi.org\/10.1192\/bjo.2023.15","relation":{},"ISSN":["2056-4724"],"issn-type":[{"value":"2056-4724","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2023. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial licence (http:\/\/creativecommons.org\/licenses\/by-nc\/4.0), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e53"}}